The three currently investigated potential isatin sulfonamide derivatives, 3a (the most superior), 4b, and 4c, significantly decreased the invasive potential of liver cancer cells through decreasing heparanase expression in the HepG2 cell lysate by a comparable degree to that shown in the Dox-treated HepG2 cells. The gene discussed is HPSE; the disease is liver cancer.